NASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis $60.12 +0.46 (+0.77%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About ANI Pharmaceuticals Stock (NASDAQ:ANIP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ANI Pharmaceuticals alerts:Sign Up Key Stats Today's Range$59.55▼$60.7050-Day Range$54.32▼$63.7552-Week Range$48.20▼$70.81Volume138,730 shsAverage Volume212,538 shsMarket Capitalization$1.26 billionP/E Ratio51.38Dividend YieldN/APrice Target$77.00Consensus RatingModerate Buy Company OverviewANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Read More… This man beat out 16,000 stock pickers to earn the #1 spot (Ad)There are very few people in this world who are considered “the best” in their field. There are guys like Michael Jordan who is considered the best basketball player of all time… Or Warren Buffet who is considered the best Investor of all time… But we’ve just met a man who might be the best stock picker of all time… Right now, as we speak, he is currently ranked the #1 stock picker in North America.If you’d like to sit down with us, follow this link here. ANI Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks94th Percentile Overall ScoreANIP MarketRank™: ANI Pharmaceuticals scored higher than 94% of companies evaluated by MarketBeat, and ranked 95th out of 1,013 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingANI Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageANI Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about ANI Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth23.18% Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 23.18% in the coming year, from $3.58 to $4.41 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is 51.38, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.34.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is 51.38, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.37.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 2.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ANI Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.82% of the outstanding shares of ANI Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in ANI Pharmaceuticals has recently increased by 2.25%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.3 / 5Environmental Score-2.48 Percentage of Shares Shorted10.82% of the outstanding shares of ANI Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in ANI Pharmaceuticals has recently increased by 2.25%, indicating that investor sentiment is decreasing. News and Social Media2.0 / 5News Sentiment0.65 News SentimentANI Pharmaceuticals has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for ANI Pharmaceuticals this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 2 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $943,880.00 in company stock.Percentage Held by Insiders12.70% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ANI Pharmaceuticals' insider trading history. Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIP Stock News HeadlinesInsider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 250 Shares of StockOctober 16 at 5:06 AM | insidertrades.comANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?October 17 at 8:05 PM | finance.yahoo.comThis man predicted today’s most valuable companies more than a decade ago.How could it be that one analyst called the rise of Apple, Microsoft, Nvidia, and many of today’s best performing stocks more than a decade ago? Some might say it was luck… Others will say he was in the right place at the right time. But looking back, this analyst has made some incredible calls over his career… In fact, right now, he’s the #1 ranked stock picker in North America… To earn that title he’s beat out more than 16,000 stock market professionals. So how does one man accomplish all that? If you were to ask him, he’d give the credit to his stock rating system…. A system that has a history of predicting which stocks could soon rise by 100% or more…October 18, 2024 | DTI (Ad)Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target at $77.00October 16 at 1:43 AM | americanbankingnews.comANI Pharmaceuticals (NASDAQ:ANIP) Coverage Initiated by Analysts at Piper SandlerOctober 14, 2024 | americanbankingnews.comPiper Sandler Initiates Coverage of ANI Pharmaceuticals (ANIP) with Overweight RecommendationOctober 12, 2024 | msn.comPeeling Back The Layers: Exploring ANI Pharmaceuticals Through Analyst InsightsOctober 11, 2024 | benzinga.comANI earns bullish view at Piper Sandler on portfolio mixOctober 11, 2024 | msn.comSee More Headlines ANIP Stock Analysis - Frequently Asked Questions How have ANIP shares performed this year? ANI Pharmaceuticals' stock was trading at $55.14 on January 1st, 2024. Since then, ANIP shares have increased by 9.0% and is now trading at $60.12. View the best growth stocks for 2024 here. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) released its quarterly earnings data on Tuesday, August, 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.95 by $0.07. The firm's revenue for the quarter was up 18.5% compared to the same quarter last year. Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' top institutional shareholders include Wedge Capital Management L L P NC (0.28%), Kings Path Partners LLC (0.09%) and Exchange Traded Concepts LLC (0.06%). Insiders that own company stock include Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Chad Gassert, Stephen P Carey, James G Marken, Christopher Mutz, Ori Gutwerg, Meredith Cook, Antonio R Pera, Krista Davis, Jeanne Thoma, Thomas Haughey and Patrick D Walsh. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ANI Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings8/06/2024Today10/17/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CUSIPN/A CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees642Year FoundedN/APrice Target and Rating Average Stock Price Target$77.00 High Stock Price Target$94.00 Low Stock Price Target$60.00 Potential Upside/Downside+28.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$1.60 Trailing P/E Ratio51.38 Forward P/E Ratio16.79 P/E GrowthN/ANet Income$18.78 million Net Margins5.01% Pretax Margin6.59% Return on Equity15.64% Return on Assets7.63% Debt Debt-to-Equity Ratio0.62 Current Ratio3.97 Quick Ratio3.07 Sales & Book Value Annual Sales$538.95 million Price / Sales2.34 Cash Flow$6.80 per share Price / Cash Flow8.84 Book Value$21.13 per share Price / Book2.85Miscellaneous Outstanding Shares20,973,000Free Float18,369,000Market Cap$1.26 billion OptionableOptionable Beta0.71 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:ANIP) was last updated on 10/18/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.